Evidence supporting the use of: RNA
For the health condition: Influenza

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

RNA-based therapies, specifically mRNA vaccines, have been investigated for the prevention and treatment of influenza. The most prominent scientific validation comes from recent developments in mRNA vaccine technology, as demonstrated by the success of mRNA vaccines for COVID-19. For influenza, several mRNA vaccines have reached early-phase clinical trials, such as those developed by Moderna and Pfizer/BioNTech, showing promising immunogenicity and safety profiles in animal models and initial human studies. These vaccines work by delivering synthetic mRNA encoding influenza virus proteins, prompting the immune system to produce a targeted response.

However, at present, there are no licensed mRNA (RNA-based) vaccines or therapeutics specifically approved for influenza in humans. Traditional influenza vaccines rely on inactivated or recombinant viral proteins, not RNA. While preclinical and early clinical data are encouraging, the evidence base is still limited compared to established influenza vaccines, and large-scale, phase 3 clinical trials are ongoing. Therefore, while there is clear scientific rationale and early validation for the use of RNA in influenza prevention and treatment, robust, widespread clinical evidence is not yet available, justifying a moderate rating of 2 out of 5.

More about RNA
More about Influenza

Products containing RNA

We currently have no products on Vitabase that contain this ingredient.